Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

May 13, 2020
- Cancer and COVID-19 Clinical trials expected to commence soon - Designed for anti-cancer treatment & iNKTs are synergistic with Agenus' checkpoint antibodies - Potential to clear SARS-CoV-2 virus and control harmful inflammation - COVID-19 IND expected to clear shortly LEXINGTON, Mass., May 13,
May 07, 2020
- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer - Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer
Mar 10, 2020
$15.1M Milestone from HealthCare Royalty Partners LEXINGTON, Mass., March 10, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment
Feb 06, 2020
LEXINGTON, Mass., Feb. 6, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.